Lannett Plans Seven Launches In Fiscal Year 2021

As Its Respiratory And Biosimilar Candidates ‘Remain On Track’

Launch
Lannett reports a stable first quarter of fiscal 2020, with a minor drop in sales • Source: Shutterstock

More from Biosimilars

More from Products